These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823 [TBL] [Abstract][Full Text] [Related]
29. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266 [TBL] [Abstract][Full Text] [Related]
30. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure. Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501 [TBL] [Abstract][Full Text] [Related]
31. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance. Tsagalou EP; Kanakakis J; Anastasiou-Nana MI; Drakos SG; Ntalianis AS; Malliaras K; Lazaris N; Katsaros F; Nanas JN Acute Card Care; 2009; 11(2):99-106. PubMed ID: 19353405 [TBL] [Abstract][Full Text] [Related]
32. Timing of levosimendan in cardiac surgery. Aksun M; Karahan N; Adanir T; Aran G; Yetkin U; Oztürk T; Sencan A; Ozgürbüz U; Gürbüz A Anadolu Kardiyol Derg; 2009 Jun; 9(3):223-30. PubMed ID: 19520657 [TBL] [Abstract][Full Text] [Related]
33. [Therapy of acute decompensated heart failure with levosimendan]. Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535 [TBL] [Abstract][Full Text] [Related]
34. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226 [TBL] [Abstract][Full Text] [Related]
35. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737 [TBL] [Abstract][Full Text] [Related]
36. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Earl GL; Fitzpatrick JT Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899 [TBL] [Abstract][Full Text] [Related]
37. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. Graudins A; Najafi J; Rur-SC MP Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter? Yontar OC; Yilmaz MB; Yalta K; Tandoğan I Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125 [TBL] [Abstract][Full Text] [Related]
39. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure. Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422 [TBL] [Abstract][Full Text] [Related]